Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	8.31B -30.2%
Revenue (ttm)	8.54B +37.6%
Net Income	369.90M +27.2%
EPS	39.19 +58.9%
Shares Out	11.66M
PE Ratio	18.18
Forward PE	n/a
Dividend	1.00 (0.14%)
Ex-Dividend Date	n/a

Volume	6,900
Open	739.55
Previous Close	739.50
Day's Range	703.00 - 745.50
52-Week Range	580.00 - 1,069.98
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	May 20, 2026

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels,...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2015
• Employees: 68
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In fiscal year 2026, Remus Pharmaceuticals's revenue was 8.54 billion, an increase of 37.60% compared to the previous year's 6.20 billion. Earnings were 369.90 million, an increase of 27.24%.